Alexander J, Snoke K, Ruppert J, Sidney J, Wall M, Southwood S, Oseroff C, Arrhenius T, Gaeta F C, Colón S M
Cytel, San Diego, CA 92121.
J Immunol. 1993 Jan 1;150(1):1-7.
The mechanisms involved in TCR antagonism by Ag analog/MHC have been analyzed. A detailed structure-activity relationship study indicated that modification of any of the major T cell contact residues of the peptide molecule can yield a powerful antagonist. It was also shown that as the analog structure increased in similarity to the Ag, the capacity to antagonize Ag-TCR interaction increased up to the point that the analogs themselves became antigenic. These data strongly suggest an affinity-related mechanism whereby a certain affinity is required for signaling through the TCR, and that below this level there can be sufficient affinity to engage the receptor such that triggering does not occur and antagonism can be detected. Taking advantage of this information, antagonist peptides active down to the 10 nM range were engineered. Thus, this approach demonstrates for the first time a rational approach to designing effective, selective low m.w. compounds with high potential in treatment of allergies and autoimmune diseases.
已对Ag类似物/MHC介导的TCR拮抗作用所涉及的机制进行了分析。一项详细的构效关系研究表明,肽分子任何一个主要T细胞接触残基的修饰都可产生强效拮抗剂。研究还表明,随着类似物结构与Ag的相似性增加,拮抗Ag-TCR相互作用的能力也随之增强,直至类似物自身具有抗原性。这些数据有力地表明了一种与亲和力相关的机制,即通过TCR进行信号传导需要一定的亲和力,而低于此水平时,虽有足够亲和力与受体结合,但不会引发触发反应,从而可检测到拮抗作用。利用这一信息,设计出了活性低至10 nM范围的拮抗肽。因此,该方法首次证明了一种合理的方法,可用于设计在治疗过敏和自身免疫性疾病方面具有高潜力的有效、选择性低分子量化合物。